

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

Santhera gibt den Vollzug des Umtauschangebots für die Wandelanleihe per 4. Mai 2021 bekannt

Pratteln, Schweiz, 3. Mai 2021 - Santhera Pharmaceuticals (SIX: SANN) gibt bekannt, dass das am 25. März 2021 angekündigte Umtauschangebot für die CHF 60 Millionen Wandelanleihe am 4. Mai 2021 vollzogen wird.

Mit dem Rückkaufsinserat vom 25. März 2021 (das **Rückkaufsinserat**) veröffentlichte Santhera Pharmaceuticals Holding AG ein Angebot zum Umtausch der ausstehenden CHF 60 Millionen 5%-Wandelanleihe mit Fälligkeit 2022 (die **2017/22 Wandelanleihe**) nach den im Rückkaufsinserat aufgeführten Konditionen (das **Umtauschangebot**). Das Umtauschangebot wurde von Anleiensgläubigern in Bezug auf die 2017/22 Wandelobligationen mit einem Gesamtnennbetrag von CHF 44'845'000 angenommen, was 74.7% der sich im Umlauf befindlichen 2017/22 Wandelanleihe entspricht.

Vollzug

Santhera hat entschieden, das Umtauschangebot am 4. Mai 2021 zu vollziehen. Das Umtauschangebot wird über das Bankensystem abgewickelt. Mit dem Vollzug wird auf die Erfüllung aller Angebotsbedingungen (b), (c), (d) und (e), wie im Rückkaufsinserat definiert, die bis zu diesem Datum nicht erfüllt sind, verzichtet.

Inhaber von 2017/22 Wandelobligationen, die das Umtauschangebot nicht angenommen haben, bleiben Anleiensgläubiger gemäss den Bedingungen der 2017/22 Wandelanleihe.

Die Gesellschaft wird den Wandelpreis am 4. Mai 2021 bekannt geben. Die Abstimmung der Anleiensgläubiger über die Restrukturierung der 2017/22 Wandelanleihe, die der Anleiensgläubigerversammlung am 8. März 2021 vorgeschlagen worden war, ist nun abgeschlossen und hat keine Zweidrittelmehrheit erreicht.

Stifel Nicolaus Europe Limited wurde von der Gesellschaft als alleiniger Finanzberater beauftragt.

Zugehörige Dokumente

Rückkaufsinserat (Tausch der vorrangigen unbesicherten Wandelanleihe über CHF 60'000'000 mit Fälligkeit 2022): <https://www.santhera.de/investors-and-media/investor-toolbox/umtauschangebot-anleihe>
Vorläufiger Emissions- und Kotierungsprospekt für die Neue Anleihe: <https://www.santhera.de/investors-and-media/investor-toolbox/umtauschangebot-anleihe>

Unternehmenskalender

22. Juni 2021 Generalversammlung

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

Über Santhera

Santhera Pharmaceuticals (SIX: SANN), ein Schweizer Spezialitätenpharmaunternehmen, ist auf die Entwicklung und Vermarktung innovativer Medikamente für seltene neuromuskuläre und pulmonale Erkrankungen mit hohem medizinischem Bedarf fokussiert. Santhera hat eine weltweite Exklusivlizenz für alle Indikationen für Vamorolone, ein first-in-class dissoziatives Steroid mit neuartigem Wirkmechanismus, welches derzeit in einer Zulassungsstudie bei Patienten mit DMD als Alternative zu Standard-Kortikosteroiden getestet wird. Die klinische Pipeline umfasst auch Lonodelestat (POL6014) zur Behandlung von Mukoviszidose (CF) und anderen neutrophilen Lungenerkrankungen und einen explorativen Gentherapieansatz für kongenitale Muskeldystrophien. Santhera hat die Ex-Nordamerika-Rechte an seinem ersten zugelassenen Produkt, Raxone® (Idebenon), zur Behandlung von Leber hereditärer Optikusatrophie (LHON) an Chiesi Group lizenziert. Weitere Informationen unter www.santhera.com.

Raxone® ist eine eingetragene Marke von Santhera Pharmaceuticals.

Für weitere Auskünfte wenden Sie sich bitte an:

public-relations@santhera.com oder

Eva Kalias, Head External Communications

Tel.: +41 79 875 27 80

eva.kalias@santhera.com

Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

Offer Restrictions

The Exchange Offer is not being made and will not be made, directly or indirectly, in any country or jurisdiction in which the Exchange Offer would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require the Company or any of its subsidiaries to change or amend the terms or conditions of the Exchange Offer in any material way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Exchange Offer. It is not intended to extend the Exchange Offer to any such country or jurisdiction. Any such document relating to the Exchange Offer must neither be distributed in any such country or jurisdiction nor be sent into such country or jurisdiction, and must not be used for the purpose of soliciting the purchase of securities of the Company by any person or entity resident or incorporated in any such country or jurisdiction.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

United States

The Exchange Offer is being made in the United States in reliance on, and compliance with, Section 14(e) of the US Securities Exchange Act of 1934 and Regulation 14E thereunder.

The Company, certain affiliated companies and the nominees or brokers (acting as agents) may make certain purchases of, or arrangements to purchase, 2017/22 Bonds outside the Exchange Offer during the period in which the Exchange Offer remains open for acceptance. If such purchases or arrangements to purchase are made they will be made outside the United States and will comply with applicable law, including the Exchange Act.

The Company as the offeror is a Swiss company. Information distributed in connection with the Exchange Offer is subject to Swiss disclosure requirements that are different from those of the United States. Financial statements and financial information included herein are prepared in accordance with Swiss accounting standards that may not be comparable to the financial statements or financial information of United States companies.

It may be difficult for you to enforce your rights and any claim you may have arising under the U.S. federal securities laws in respect of the Exchange Offer, since the Company is located in Switzerland and all of its officers and directors are residents of Switzerland or elsewhere outside of the United States. You may not be able to sue the Company or its officers or directors in a Swiss court or another court outside the United States for violations of the U.S. securities laws. Finally, it may be difficult to compel the Company and its affiliates to subject themselves to a U.S. court's judgment.

United Kingdom

The communication of this publication and any other documents or materials relating to the Exchange Offer is not being made and such documents and/or materials have not been approved by an authorized person for the purposes of section 21 of the Financial Services and Markets Act 2000, as amended. Accordingly, such documents and/or materials are not being distributed to, are not directed at and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to persons within the United Kingdom falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the **Order**)) or falling within Article 43(2) of the Order, or to other persons to whom it may lawfully be communicated (together "relevant persons"). The investment activity to which this document relates will only be engaged in with relevant persons and persons who are not relevant persons should not rely on it.

European Economic Area

In any Member State of the European Economic Area (the **EEA**) or in the United Kingdom (each, a Relevant State), this Notice is only addressed to, and is only directed at, qualified investors in that Relevant State within the meaning of Regulation (EU) 2017/1129 (the **Prospectus Regulation**). Each person in a Relevant State who receives any communication in respect of the Exchange Offer contemplated in this Notice will be deemed to have represented, warranted and agreed to and with the Company and the Tender Agent that it is a qualified investor within the meaning of the Prospectus Regulation. The 2017/22 Bonds have not been admitted to trading on a regulated market in the EEA or in the United Kingdom.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

Switzerland

This communication qualifies as advertisement pursuant to the Swiss Financial Services Act (**FinSA**) and does neither constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG nor a prospectus nor a key information document within the meaning of the FinSA. Investors should make their decision to accept the Exchange Offer solely based on the Notice of a Repurchase Offer (Exchange of CHF 60,000,000 Senior Unsecured Convertible Bonds due 2022) and the preliminary offering and listing prospectus regarding the New Bonds, each dated March 25, 2021 which, subject to compliance with applicable securities laws, is accessible via <https://www.santhera.com/investors-and-media/investor-toolbox/bond-exchange-offering>. Investors are furthermore advised to consult their bank or financial adviser before making any investment decision.

###